Department of Chemistry, University of Manchester

Nutromics attracts world leaders in the emerging field of DNA-based sensing to join its Biosensor Advisory Board

Retrieved on: 
Friday, July 28, 2023
Columbia University, Scientia, University, Thomson Reuters, Johns Hopkins School of Medicine, Believer, Protein folding, University of California, Associate, Biology, Johns Hopkins University, Department of Chemistry, University of Manchester, Johns Hopkins, University of North Carolina at Chapel Hill, La Trobe Institute for Molecular Science, Pharmaceutical industry, Medical imaging, Chemistry, Pharmacology

Nutromics is a leader in continuous DNA-based sensing and is developing the world's first precision diagnostic platform.

Key Points: 
  • Nutromics is a leader in continuous DNA-based sensing and is developing the world's first precision diagnostic platform.
  • The board consists of researchers from Columbia University, University of California, Johns Hopkins, North Carolina State University, and the University of New South Wales.
  • "We've attracted the most acclaimed researchers in the field because we're world leaders in the space of continuous DNA-based sensing," said Nutromics CEO and co-founder Peter Vranes.
  • To achieve this, we need to collaborate with the most experienced experts, and this advisory board represents a major step in that direction."

ProQR Therapeutics to Host Virtual R&D Event on March 29, 2023

Retrieved on: 
Tuesday, February 28, 2023
Therapy, Doctor of Philosophy, University, Davis, ADAR, RNA-binding protein, Department of Chemistry, University of Manchester, UC, Webcast, Q&A, Adenosine, Enzyme, NIH, EDT, ProQR, Human, Beal, RNA, Management

LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced that the Company will host a virtual R&D event on Wednesday, March 29, 2023 from 10:00 am until 12:30 pm EDT, including an Analyst Q&A session with members of the ProQR Management Team.

Key Points: 
  • LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced that the Company will host a virtual R&D event on Wednesday, March 29, 2023 from 10:00 am until 12:30 pm EDT, including an Analyst Q&A session with members of the ProQR Management Team.
  • Speakers from the Company will include Daniel A. de Boer, Founder and CEO, Gerard Platenburg, Chief Scientific Officer, and René Beukema, Chief Corporate Development Officer.
  • Peter Beal, PhD, Professor in the Department of Chemistry at the University of California at Davis and ProQR Scientific Advisory Board member will also present.
  • A live webcast of the event will be available under “Events” in the “Investors & Media” section of ProQR’s website at www.proqr.com/events .

Palleon Announces Issuance of a U.S. Patent for Use of Antibody Sialidase Conjugates

Retrieved on: 
Thursday, October 13, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Anne, Ithaca College School of Humanities and Sciences, Humanities, IND, Immunity, Nobel Prize, Neoplasm, Patient, Biotechnology, Cell, Cancer, Technology, Tumor microenvironment, Drug discovery, Department, Nobel Prize in Chemistry, Science, Patent, Immunotherapy, Medication, Stanford University, Inflammation, EAGLE, School, Department of Chemistry, University of Manchester, Vaccine, Pharmaceutical industry, Palleon, Chemistry

Palleon Pharmaceuticals , a clinical-stage company pioneering glyco-immunology drug development to treat cancer and inflammatory diseases, today announced that the U.S. Patent and Trademark Office has issued Patent No.11,459,398 titled, Conjugates for Targeted Cell Surface Editing.

Key Points: 
  • Palleon Pharmaceuticals , a clinical-stage company pioneering glyco-immunology drug development to treat cancer and inflammatory diseases, today announced that the U.S. Patent and Trademark Office has issued Patent No.11,459,398 titled, Conjugates for Targeted Cell Surface Editing.
  • The patented technology is part of an exclusive license Palleon has with Stanford University and originated in the laboratory of Carolyn Bertozzi, an inventor on the patent, and a scientific co-founder of Palleon Pharmaceuticals.
  • This patent covers the use in cancer of tumor-targeted antibodies conjugated to sialidase, an enzyme that cleaves sialic acid.
  • Palleon Pharmaceuticals is a biotechnology company pioneering glyco-immunology drug development to transform the treatment of cancer and inflammatory diseases.

Sorrento Announces Publication of a Series of Novel SARS-CoV-2 Main Protease (MPRO) Inhibitors for Potential Treatment of COVID-19 Patients Infected With SARS-CoV-2 Variants Of Concern, Including Omicron

Retrieved on: 
Sunday, December 5, 2021
Patient, Private Securities Litigation Reform Act, TRPV1, Security (finance), Trial of the century, CEO, Texas A&M University, Risk, Trigeminal neuralgia, Forward-looking statement, Autoimmune disease, Protease, Cathepsin L, TMPRSS2, Cancer, Severe acute respiratory syndrome coronavirus 2, Furin, SAN, U.S. Securities and Exchange Commission, Manuscript, Pain, Vaccine, Omicron, Texas, GLOBE, Mpro, SARS, Sciatica, Antibody, FDA, ACE2, Department of Chemistry, University of Manchester, Therapy, Osteoarthritis, IC50, Department, RTX, COVID, Pharmaceutical industry, Generic drug

Other analogs of the series have been evaluated by Sorrento to develop an oral antiviral drug for treatment of patients infected with existing and emerging SARS-CoV-2 variants of concern, including Omicron.

Key Points: 
  • Other analogs of the series have been evaluated by Sorrento to develop an oral antiviral drug for treatment of patients infected with existing and emerging SARS-CoV-2 variants of concern, including Omicron.
  • The full manuscript is available at: https://pubmed.ncbi.nlm.nih.gov/34242492/
    SARS-CoV-2 main protease (MPro) is a key enzyme for the viral life cycle including virus entry, replication and packaging.
  • MPro is highly conserved in all discovered SARS CoV-2 variants and is identified as a critical target for developing broad-spectrum antiviral drugs.
  • Sorrento has collaborated with Professor Lius lab at Texas A&M University to evaluate analogs in the series to develop an oral anti-COVID drug.